- Cannabix Technologies (CSE:BLO) completed its first commercial sale of its Marijuana Breath Test system to a major construction company in the Pacific Northwest
- The technology is designed to detect recent cannabis use within a four‑hour window, addressing limitations of traditional drug tests
- The company expects growing demand from safety‑sensitive industries seeking more relevant impairment‑related testing tools
- Cannabix stock (CSE:BLO) last traded at $0.66
Cannabix Technologies (CSE:BLO) has completed the first commercial sale of its Marijuana Breath Test (MBT) system to a major construction firm in the U.S. Pacific Northwest. The units were delivered through an authorized reseller, marking a significant milestone in the company’s transition from development to commercial deployment.
The buyer—a large regional contractor involved in industrial, civil, and commercial projects—sought a modernized solution to assess recent cannabis use among employees working in safety‑sensitive environments. According to Cannabix, the request aligns with growing demand for impairment‑relevant testing tools across high‑risk industries.
Addressing risks in safety‑sensitive industries
The construction sector continues to report one of the nation’s highest workplace injury rates. Increased cannabis consumption throughout the United States has heightened concerns among employers operating heavy equipment, active job sites, and other high‑risk settings. Traditional drug tests such as urine, saliva, and hair analyses detect cannabis use that may have occurred days or weeks earlier, offering little correlation to real‑time impairment.
These legacy methods can also create legal and labor‑relations challenges in jurisdictions where recreational or medical cannabis use is permitted. Employees may test positive for off‑duty, lawful consumption that bears no relevance to their ability to safely perform job duties. Industries facing strict safety requirements—including construction, transportation, logistics, warehousing, and manufacturing—are increasingly seeking methods that distinguish recent use from historical use.
MBT technology: Built for detection of recent cannabis use
Cannabix’s Marijuana Breath Test is designed specifically to detect delta‑9 THC—the primary psychoactive component of cannabis—in human breath within a window of roughly four hours after use, at concentrations above 5 pg/L. This period aligns more closely with the timeframe associated with peak impairment, offering employers a testing metric that is both timely and relevant for safety decisions.
The MBT system includes:
- Cannabix Breath Collection Unit (BCU)
- Single‑use disposable breath cartridges
- Laboratory developed test method by Omega Laboratories, utilizing liquid chromatography–mass spectrometry (LC‑MS) for confirmatory analysis.
Omega Laboratories—an accredited forensic drug‑testing provider with more than 25 years of experience—serves as Cannabix’s strategic laboratory partner and performs sample analyses for the MBT system.
Positioning for market expansion
The company states that this initial sale represents a major step in its commercialization strategy as it anticipates broader interest from large employers facing regulatory expectations, insurance requirements, and operational pressures related to impairment‑risk management. High‑volume industrial sectors with stringent safety mandates are considered near‑term market opportunities.
Cannabix continues to scale its production capabilities and collaborate with resellers as it aims to establish the MBT as a standard tool for detecting recent cannabis use in workplaces where safety is critical.
Scientific findings cited by the company indicate that delta‑9 THC remains detectable in breath for approximately two to four hours—closely matching the period in which impairment is most likely—making breath analysis a highly relevant indicator for employers evaluating fitness‑for‑duty.
Leadershup commentary
“As cannabis use continues to expand across the United States, safety-sensitive industries are struggling with outdated drug testing methods that do not reflect real-world workplace needs,” Rav Mlait, Cannabix CEO, said in a news release. “Our Marijuana Breath Test provides a modern, scientifically grounded way to identify recent cannabis use in a fair and non-invasive manner. This first commercial delivery to a major construction contractor is an important milestone that supports safer operations and more informed decision-making.”
The Marijuana Breath Test enables the immediate, non-invasive detection of delta-9 THC, the primary psychoactive compound in cannabis, within 4 hours of consumption at levels above 5 pg/L, closely aligning it with the period of peak impairment. A peer-reviewed study in the Journal of Analytical Toxicology published in March 2026 validated these specifications.
About Cannabix
Cannabix Technologies develops marijuana and alcohol breath technologies for workplaces, law enforcement and other safety-sensitive settings.
Cannabix stock (CSE:BLO) last traded at $0.66 and has risen 6.45 per cent since this time last year.
Join the discussion: Find out what investors are saying about this cannabis breathalyzer stock on the Cannabix Technologies Inc. Bullboard and make sure to explore the rest of Stockhouse’s stock forums and message boards.
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.